|Eris Lifesciences IPO Prospectus
|What Are Analysts Saying?
|Eris Lifesciences (IPO) is Strong on B2D|
|Punit Jain, 19 Jun 2017|
|While the IPO is an exit opportunity for some investors, it empowers Eris for the next phase of growth by providing visibility and prestige, and the ability to raise fresh funds at low cost. This IPO offering is rated BUY, and investors can invest with a 2 year perspective.|
|Eris Lifesciences IPO: Rudra Shares are 'Neutral' on this IPO|
|Rudra Shares and Stock Brokers, 19 Jun 2017|
|Though the company financials are healthy, but major revenue of the company comes from its top 10 brands accounting to 74% in India. Considering the cut throat competition in the pharma sector we are NEUTRALfor this IPO.|
|Intraday Derivatives Call: Buy BANKNIFTY 22JUN 23500 CE above 95 with stop-loss 65|
|Nirmal Bang, 16 Jun 2017|
|Technically the index has been moving in a higher top and higher bottom formation, indicating positive bias. The 23500 CE has the highest OI indicating that the index is now likely to move towards 23600-23700 levels in near term.|
|Jainam Research recommend to 'subscribe' to the Eris Lifesciences IPO|
|Jainam Research, 15 Jun 2017|
|According to Jainam Research, the company is focusing on high margin therapeutic areas of cardiovascular, anti-diabetics, vitamins, gastroenterology & anti-infectives, prime focus is on metro cities and class 1 towns in India.|
|Eris Lifescience IPO: HEM Securities recommend to 'Subscribe' on issue|
|Hem Securities, 13 Jun 2017|
|According to Hem Securities, at price band of Rs 600-603, company is bringing the issue at p/e multiple of around 34.05-34.22 on FY17 Eps of Rs 17.62/share. Its strong financial with zero debt status makes it a strong candidate for investment.|
| Issue Details |
|Open Date: 16 Jun 17|
|Close Date: 20 Jun 17|
Rs. 1741.16 Cr
|Min Application Amount:
|Min bid (No. of shares): 24
|Listing Exchanges: BSE, NSE|
| About the Company|
|"Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives."
| Objective of the Issue|
|"Objects of the Issue:
The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. For the sale of up to 28,875,000 Equity Shares by the Selling Shareholders."
| Subscription Details|
|| No of times
|Qualified Institutional Investor
|Non Institutional Investor